TLR7 and melanoma: We previously described that imiquimod (TLR7‐L) treatment in melanoma‐bearing mouse models can reverse the tolerogenic activity of tumor‐infiltrating pDCs, triggering their cytotoxic functions and impeding tumor vascularisation.46